Significant mutations include somatic inactivation of MEN1, EIF1AX, and ARID1A, with around 5% of patients having MEN1 syndrome, a rare disorder that predisposes patients to developing tumors in endocrine glands and organs (39, 40). This evidence concerns the gene ARID1A and multiple endocrine neoplasia type 1.